litlas
Log inCreate account

Mark X. Sliwkowski

Active 1992–2024

59
Papers
30,512
Citations
57
h-index
59
i10-index

Citations

Citations per year for Mark X. Sliwkowski1984: 1 citations1992: 6 citations1993: 26 citations1994: 46 citations1995: 94 citations1996: 78 citations1997: 125 citations1998: 83 citations1999: 97 citations2000: 130 citations2001: 136 citations2002: 155 citations2003: 240 citations2004: 261 citations2005: 297 citations2006: 275 citations2007: 301 citations2008: 295 citations2009: 273 citations2010: 300 citations2011: 350 citations2012: 352 citations2013: 420 citations2014: 480 citations2015: 358 citations2016: 305 citations2017: 267 citations2018: 260 citations2019: 831 citations2020: 721 citations2021: 680 citations2022: 573 citations2023: 419 citations2024: 663 citations2025: 345 citations2026: 16 citations1985–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,417 citing papers, 33.4% of this breakdownChina: 909 citing papers, 8.9% of this breakdownUnited Kingdom: 596 citing papers, 5.8% of this breakdownGermany: 509 citing papers, 5% of this breakdownItaly: 430 citing papers, 4.2% of this breakdownJapan: 364 citing papers, 3.6% of this breakdownFrance: 323 citing papers, 3.1% of this breakdownSwitzerland: 289 citing papers, 2.8% of this breakdownCanada: 278 citing papers, 2.7% of this breakdownSpain: 271 citing papers, 2.6% of this breakdownIndia: 232 citing papers, 2.3% of this breakdownSouth Korea: 211 citing papers, 2.1% of this breakdown
0%33.4%Other 23.5%

Institutions

Fields

  • Medicine64%
  • Biochemistry, Genetics and Molecular Biology22.4%
  • Chemistry3.2%
  • Neuroscience2.8%
  • Immunology and Microbiology2.5%
  • Computer Science1.9%
  • Other3.2%

Topics

  • HER2/EGFR in Cancer Research15.3%
  • Monoclonal and Polyclonal Antibodies Research12.1%
  • Lung Cancer Treatments and Mutations3.2%
  • Glycosylation and Glycoproteins Research2.9%
  • Peptidase Inhibition and Analysis2.1%
  • CAR-T cell therapy research1.9%
  • Other62.5%

Coauthors

All papers

Open in search
  1. Untangling the ErbB signalling network

    Authors: Yosef Yarden, Mark X. Sliwkowski - Nature Reviews Molecular Cell Biology 2001 cited by 6,942

  2. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

    Authors: Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, Lisa Crocker, Kathryn L. Parsons, Elaine Mai, Walter A. Blättler, John M. Lambert, Ravi Chari, Robert J. Lutz, Wai Lee Wong, Frederic S. Jacobson, Hartmut Koeppen, Ralph Schwall, Sara Kenkare-Mitra, Susan D. Spencer, Mark X. Sliwkowski - Cancer Research 2008 cited by 1,678

  3. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

    Authors: Jennifer L. Stamos, Mark X. Sliwkowski, Charles Eigenbrot - Journal of Biological Chemistry 2002 cited by 1,526

  4. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

    Authors: Jagath R. Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D. Leipold, Sylvia Weir, Yvonne Chen, Michelle Simpson, Siao Ping Tsai, Mark S. Dennis, Yanmei Lu, Y. Gloria Meng, Carl Ng, Jihong Yang, Chien C Lee, Eileen Duenas, Jeffrey Gorrell, Viswanatham Katta, Amy Kim, Kevin S. McDorman, Kelly M. Flagella, Rayna Venook, Sarajane Ross, Susan D. Spencer, Wai Lee Wong, Henry B. Lowman, Richard Vandlen, Mark X. Sliwkowski, Richard H. Scheller, Paul Polakis, William Mallet - Nature Biotechnology 2008 cited by 1,354

  5. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

    Authors: Ben‐Quan Shen, Keyang Xu, Luna Liu, Helga Raab, Sunil Bhakta, Margaret Kenrick, Kathryn Parsons-Reponte, Janet Tien, Shang‐Fan Yu, Elaine Mai, Dongwei Li, Jay Tibbitts, Jakub Baudys, Ola M. Saad, Suzie J. Scales, Paul J McDonald, Philip E. Hass, Charles Eigenbrot, Trung Van Nguyen, Willy A. Solis, Reina N. Fuji, Kelly M. Flagella, Darshana Patel, Susan D. Spencer, Leslie A. Khawli, Allen Ebens, Wai Lee Wong, Richard Vandlen, Surinder Kaur, Mark X. Sliwkowski, Richard H. Scheller, Paul Polakis, Jagath R. Junutula - Nature Biotechnology 2012 cited by 999

  6. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

    Authors: Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons, Gail D. Lewis Phillips, Mark X. Sliwkowski - Breast Cancer Research and Treatment 2010 cited by 533

  7. Treatment of HER2-positive breast cancer: current status and future perspectives

    Authors: Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni - Nature Reviews Clinical Oncology 2011 cited by 871

  8. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

    Authors: Matthew C. Franklin, Kendall D. Carey, F.F. Vajdos, Daniel J. Leahy, Abraham M. de Vos, Mark X. Sliwkowski - Cancer Cell 2004 cited by 1,115

  9. Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

    Authors: Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Carter T. Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski - Cancer Cell 2009 cited by 831

  10. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

    Authors: Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, Walter C. Darbonne, Daniela Bumbaca, Ben‐Quan Shen, Xiaoyan Du, Ola M. Saad, Kristin Harden Bowles, Steve Olsen, Gail D. Lewis Phillips, Dylan P. Hartley, Mark X. Sliwkowski, Sandhya Girish, Donna M. Dambach, Vanitha Ramakrishnan - Clinical Cancer Research 2014 cited by 211

  11. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

    Authors: Guangmin Li, Jun Guo, Ben‐Quan Shen, Daniela Bumbaca Yadav, Mark X. Sliwkowski, Lisa Crocker, Jennifer A. Lacap, Gail D. Lewis Phillips - Molecular Cancer Therapeutics 2018 cited by 184

  12. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates

    Authors: Niña G. Caculitan, Josefa Chuh, Yong Ma, Donglu Zhang, Katherine R. Kozak, Yichin Liu, Thomas H. Pillow, Jack Sadowsky, Tommy K. Cheung, Qui Phung, Benjamin Haley, Byoung-Chul Lee, Robert W. Akita, Mark X. Sliwkowski, Andrew G. Polson - Cancer Research 2017 cited by 154

  13. A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

    Authors: Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, Thinh Q. Pham, Xander Munroe, Klaus P. Hoeflich, Mark X. Sliwkowski, Howard M. Stern - Cancer Research 2008 cited by 646

  14. Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

    Authors: Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy D. Miller, Fabrice André, Howard A. Burris, Kathy S. Albain, Nadia Harbeck, Véronique Dièras, Diana Crivellari, Fang Ting Liang, Ellie Guardino, Steven R. Olsen, Lisa Crocker, Mark X. Sliwkowski - Clinical Cancer Research 2013 cited by 199

  15. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results

    Authors: Gail D. Lewis Phillips, Guangmin Li, Jun Guo, Shang‐Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas H. Pillow, BinQing Wei, Jack Sadowsky, Douglas D. Leipold, Tim Wilson, Amrita V. Kamath, Michael Mamounas, M. Violet Lee, Ola M. Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian E. Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho - Nature Communications 2024 cited by 46

  16. Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

    Authors: Ian E. Krop, Muralidhar Beeram, Shanu Modi, Suzanne F. Jones, Scott N. Holden, Wei Yu, Sandhya Girish, Jay Tibbitts, Joo‐Hee Yi, Mark X. Sliwkowski, Fred Jacobson, Stuart Lutzker, Howard A. Burris - Journal of Clinical Oncology 2010 cited by 596

  17. Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin

    Authors: Cary D. Austin, Ann M. De Mazière, Paul I. Pisacane, Suzanne M. van Dijk, Charles Eigenbrot, Mark X. Sliwkowski, Judith Klumperman, Richard H. Scheller - Molecular Biology of the Cell 2004 cited by 489

  18. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

    Authors: Antony W. Burgess, Hyun‐Soo Cho, Charles Eigenbrot, Kathryn M. Ferguson, Thomas Garrett, Daniel J. Leahy, Mark A. Lemmon, Mark X. Sliwkowski, Colin W. Ward, Shigeyuki Yokoyama - Molecular Cell 2003 cited by 900

  19. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

    Authors: David B. Agus, Robert W. Akita, William D. Fox, Gail D. Lewis Phillips, Brian Higgins, Paul I. Pisacane, Julie A. Lofgren, Charles Tindell, Douglas P. Evans, Krista Maiese, Howard I. Scher, Mark X. Sliwkowski - Cancer Cell 2002 cited by 888

  20. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Jagath R. Junutula, Kelly M. Flagella, Richard Graham, Kathryn L. Parsons, Edward Ha, Helga Raab, Sunil Bhakta, Trung Van Nguyen, Debra L. Dugger, Guangmin Li, Elaine Mai, Gail D. Lewis Phillips, Hajime Hiraragi, Reina N. Fuji, Jay Tibbitts, Richard Vandlen, Susan D. Spencer, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski - Clinical Cancer Research 2010 cited by 292

  21. Antibody Therapeutics in Cancer

    Authors: Mark X. Sliwkowski, Ira Mellman - Science 2013 cited by 541

  22. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

    Authors: Gabriele Schaefer, Lauric Haber, Lisa Crocker, Steven Shia, Lily Shao, Donald Dowbenko, Klára Tótpál, Anne Wong, Chingwei V. Lee, Scott Stawicki, Robyn Clark, Carter T. Fields, Gail D. Lewis Phillips, Rodney A. Prell, Dimitry M. Danilenko, Yvonne Franke, Jean-Philippe Stéphan, Ji‐Young Hwang, Yan Wu, Jenny Boström, Mark X. Sliwkowski, Germaine Fuh, Charles Eigenbrot - Cancer Cell 2011 cited by 335

  23. Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

    Authors: Kendall D. Carey, Andrew J. Garton, Maria S. Romero, Jennifer Kahler, Stuart Thomson, Sarajane Ross, Frances Park, John D. Haley, Neil W. Gibson, Mark X. Sliwkowski - Cancer Research 2006 cited by 443

  24. Oncogenic ERBB3 Mutations in Human Cancers

    Authors: Bijay S. Jaiswal, Noelyn M. Kljavin, Eric Stawiski, Emily Chan, Chaitali Parikh, Steffen Durinck, Subhra Chaudhuri, Kanan Pujara, Joseph Guillory, Kyle A. Edgar, Vasantharajan Janakiraman, Rolf‐Peter Scholz, Krista K. Bowman, Maria Lorenzo, Hong Li, Jiansheng Wu, Wenlin Yuan, Brock A. Peters, Zhengyan Kan, Jeremy Stinson, Michelle Mak, Zora Modrušan, Charles Eigenbrot, Ron Firestein, Howard M. Stern, Krishnaraj Rajalingam, Gabriele Schaefer, Mark Merchant, Mark X. Sliwkowski, Frédéric J. de Sauvage, Somasekar Seshagiri - Cancer Cell 2013 cited by 347